Berlin, Germany

Daniela Fliegner

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 15.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: **Daniela Fliegner: Innovator in Pharmacology from Berlin**

Introduction

Daniela Fliegner is an accomplished inventor based in Berlin, Germany. Her innovative work in pharmacology has made significant contributions to the treatment of various diseases, showcasing her dedication to medical advancements.

Latest Patents

Fliegner holds a patent for "Positive Allosteric Modulators of Muscarinic M2 Receptor." This patent focuses on 7-substituted 1-arylnaphthyridine-3-carboxamides, which are novel compounds that act as positive allosteric modulators. The application emphasizes their use in the treatment and prevention of diseases, particularly cardiovascular and renal disorders. It highlights the processes for their preparation and the potential for their inclusion in medicament production.

Career Highlights

Daniela Fliegner is associated with Bayer Pharma Aktiengesellschaft, a prominent global pharmaceutical company. Her work at Bayer allows her to engage in cutting-edge research that propels medical science forward. Her dedication and innovative spirit have established her as an influential figure within her field.

Collaborations

Fliegner collaborates with notable professionals such as Henrik Teller and Alexander Straub. These partnerships enhance her research capabilities, fostering a rich environment for innovation and discovery in pharmacology.

Conclusion

Daniela Fliegner's contributions to the field of pharmacology through her patent on positive allosteric modulators emphasize her role as a forward-thinking inventor. Her collaboration with esteemed colleagues at Bayer positions her at the forefront of developing essential treatments for numerous health conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…